Tixagevimab and cilgavimab: Can we see more recommendations for monoclonal antibodies beyond COVID-19 vaccination
Yükleniyor...
Tarih
2022
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Cambridge University Press
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Nearly three years after its detection, coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome CoV-2, is still a life-threatening global pandemic health disease that contributed to a high progression and mortality. This imposes the scientific researching efforts to hold intense interest directed to explore for the development and optimizing different interventions to COVID-19 infection. This commentary summarizes the potential clinical benefits for the recently authorized immunotherapy combination of tixagevimab and cilgavimab monoclonoal antibodies for the prevention and treatment of COVID-19.
Açıklama
Anahtar Kelimeler
Cilgavimab, COVID-19, Monoclonal Antibodies, Tixagevimab, Vaccination
Kaynak
Disaster Medicine and Public Health Preperadness
WoS Q Değeri
Q3
Scopus Q Değeri
Q2
Cilt
Sayı
Künye
Al-Taie A. Tixagevimab and Cilgavimab: Can We See More Recommendations for Monoclonal Antibodies beyond COVID-19 Vaccination. Disaster Med Public Health Prep. 2022 Jun 8:1-5. doi: 10.1017/dmp.2022.150. Epub ahead of print. PMID: 35672931.
